After 28 years with Gilead Sciences, CEO John Milligan has announced he will step down from the role and “move on to different opportunities.”
During Milligan’s last 12 months at Gilead, he oversaw the firm’s acquisition of chimeric antigen receptor (CAR) T-cell-focused Kite Pharma, and the US Food and Drug Administration’s (FDA) second approval for a CAR T-cell therapy, Yescarta (axicabtagene ciloleucel).
“It has been an honour to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the board and I have agreed it is a good time to turn the reins over to a new leader,” said Milligan.
“I’m looking forward to a well-deserved break and then will move on to new and different opportunities,” he added.
According to Gilead, Milligan will remain in his current position until the end of the year, to allow the board of directors time to hire a successor.
“We are excited about our growth potential, and intend to hire a CEO who will build on the foundation that John Milligan has put in place and execute on our ambitious goals for the future,” said John Martin, chairman of the board of directors.